Last Updated: May 1, 2026

Claims for Patent: 11,124,578

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,124,578

Title:	Method of treating transplant rejection with silent Fc variants of anti-CD40 antibodies
Abstract:	The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
Inventor(s):	Heusser Christoph, Rush James, Vincent Karen
Assignee:	NOVARTIS AG
Application Number:	US16399250
Patent Claims:

Details for Patent 11,124,578

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	⤷ Start Trial	2039-04-30
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	⤷ Start Trial	2039-04-30
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	⤷ Start Trial	2039-04-30
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	⤷ Start Trial	2039-04-30
Immunex Corporation	ENBREL	etanercept	Injection	103795	February 01, 2007	⤷ Start Trial	2039-04-30
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	September 14, 2017	⤷ Start Trial	2039-04-30
Immunex Corporation	ENBREL	etanercept	Injection	103795		⤷ Start Trial	2039-04-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 11,124,578

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Africa	201302532	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2012065950	⤷ Start Trial
Uruguay	39292	⤷ Start Trial
Uruguay	33728	⤷ Start Trial
United States of America	9828433	⤷ Start Trial
United States of America	9688768	⤷ Start Trial
United States of America	9221913	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.